Price Crosses Moving Average
|Bid||22.71 x 800|
|Ask||23.49 x 800|
|Day's Range||23.32 - 23.79|
|52 Week Range||13.67 - 27.80|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||25.25|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.85|
These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been previously treated with one novel hormonal therapy. CONTACT-02 is part of a clinical trial collaboration between Exelixis and Roche that includes two additional phase 3 pivotal trials – CONTACT-01 in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy, which was initiated in June, and the planned CONTACT-03 trial in patients with metastatic renal cell carcinoma (RCC) who previously received an immune checkpoint inhibitor.
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 PM EDT / 12:30 PM PDT.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor (ICI) and platinum-containing chemotherapy. Two additional phase 3 pivotal trials in metastatic castration-resistant prostate cancer (CRPC; CONTACT-02) and renal cell carcinoma (RCC; CONTACT-03) are planned as part of the clinical trial collaboration between Exelixis and Roche.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
Today we will run through one way of estimating the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the...
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Exelixis, Inc. (NASDAQ:EXEL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM Eastern Time. ...
Exelixis : "I've liked this one all the way," said Jim Cramer to a caller during the 'Lightning Round' of Mad Money Thursday night. Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. In this daily bar chart of EXEL, below, we can see that prices made a huge upside price gap or void last month.
Exelixis (NASDAQ:EXEL) shares have had a really impressive month, gaining 60%, after some slippage. And the full year...
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
Exelixis shares was roughly unchanged Tuesday, holding gains after a massive 21% jump on Monday amid positive test results for a new cancer medicine. The South San Francisco-based company saw a positive improvement to its IBD Relative Strength (RS) Rating on Tuesday, with an upgrade from 84 to 95. The rating upgrade came after Exelixis and partner Bristol-Myers Squibb on Monday announced positive results in a Phase 3 test of a kidney cancer treatment.
The company's stock soared Monday on results from a late-stage clinical trial pairing with a major cancer immunotherapy.